ISO 13485:2016 Lead Implementer Free Practice Test — 30 Questions

Question 1

A medical device manufacturer, \"MediCorp Innovations,\" relies on an external calibration laboratory, \"Precision Calibrations Inc.,\" to calibrate the reference standards used in their quality control testing of implantable cardiac pacemakers. MediCorp Innovations, as part of their ISO 13485:2016 compliant quality management system, is conducting a routine audit of Precision Calibrations Inc. to ensure continued compliance with ISO/IEC 17025:2017. During the audit, the quality manager of MediCorp, Isabella Rodriguez, discovers that Precision Calibrations Inc. uses a specific reference standard, a high-precision digital multimeter, which is crucial for calibrating MediCorp\'s testing equipment. Precision Calibrations Inc. presents a calibration certificate for this multimeter, issued by another calibration service. What is the MOST critical action Isabella Rodriguez must take to verify the validity and traceability of Precision Calibrations Inc.\'s calibration process related to this multimeter, ensuring the integrity of MediCorp\'s medical device testing and adherence to regulatory requirements such as 21 CFR Part 820?

Accepted Answer

Verify that the calibration certificate for the digital multimeter demonstrates traceability to a recognized national metrology institute (NMI), or when such traceability is not possible, demonstrate competence and measurement reliability.

Question 2

MedTech Solutions, a manufacturer of implantable cardiac pacemakers certified to ISO 13485:2016, operates an in-house testing laboratory that performs critical biocompatibility and performance testing of pacemaker components. The data generated by this lab is used to support regulatory submissions to the FDA and Notified Bodies under the EU MDR. During an internal audit, concerns are raised about the lack of formal accreditation for the testing lab. While the lab operates under the company\'s ISO 13485 QMS and undergoes regular internal audits, it does not have ISO/IEC 17025 accreditation. Considering the criticality of the testing data for regulatory compliance and product safety, what is the MOST appropriate course of action for MedTech Solutions regarding the in-house testing laboratory?

Accepted Answer

Pursue ISO/IEC 17025 accreditation for the in-house testing laboratory to demonstrate technical competence and ensure the reliability of test results for regulatory compliance.

Question 3

A clinical laboratory, \"MediTest Solutions,\" is seeking ISO/IEC 17025:2017 accreditation to enhance its credibility and ensure the reliability of its test results. During an internal audit, Dr. Anya Sharma, the quality manager, discovers that the laboratory technicians have been routinely analyzing patient samples without performing system suitability testing (SST) on their high-performance liquid chromatography (HPLC) instruments. The laboratory\'s standard operating procedures (SOPs) vaguely mention SST but do not specify the frequency, acceptance criteria, or corrective actions to be taken if SST fails. This practice has been ongoing for the past three months due to a heavy workload and staffing shortages. The HPLC instruments are used to quantify drug levels in patient blood samples, which directly influence dosage adjustments prescribed by physicians. Considering the requirements of ISO/IEC 17025:2017 and the potential impact on patient care, what is the most appropriate immediate action Dr. Sharma should take?

Accepted Answer

Halt the analysis of patient samples immediately and perform system suitability testing to ensure the analytical system is functioning correctly before resuming analysis.

Question 4

MedTech Solutions, a manufacturer of Class II medical devices, operates an in-house testing laboratory. The company\'s leadership decides to pursue ISO/IEC 17025:2017 accreditation for this lab to enhance credibility and streamline regulatory submissions in multiple global markets. Given that the laboratory is directly integrated within the manufacturing organization, what presents the MOST significant challenge for the lead implementer during the accreditation process, considering the context of ISO 13485:2016 compliance and the necessity for independent and reliable testing results? The lead implementer, Aaliyah, must ensure the laboratory’s accreditation aligns with both standards and supports the company’s overall quality objectives, whilst adhering to stringent regulatory requirements for medical device testing.

Accepted Answer

Demonstrating consistent competence and impartiality in testing activities, ensuring independence from manufacturing pressures, and establishing a robust quality management system that aligns with both ISO/IEC 17025 and ISO 13485.

Question 5

\"EnviroTest Services,\" an environmental testing laboratory, is seeking ISO/IEC 17025:2017 accreditation. During the initial assessment, the accreditation body identifies a concern regarding the laboratory\'s handling of client feedback and complaints. Specifically, the laboratory lacks a documented procedure for addressing complaints related to the interpretation of test results. Considering the requirements of ISO/IEC 17025:2017, which of the following actions is MOST critical for \"EnviroTest Services\" to implement in order to address this concern and demonstrate compliance with the standard\'s requirements for client interaction and communication?

Accepted Answer

Establish a documented procedure for receiving, evaluating, and resolving client feedback and complaints, including a process for investigating complaints related to the interpretation of test results and communicating the findings to the client.

Question 6

\"Quantum Analytics,\" a calibration laboratory specializing in high-precision instruments, is implementing ISO/IEC 17025:2017. They routinely use a validated method for calibrating oscilloscopes. The laboratory recently acquired a new, state-of-the-art digital multimeter (DMM) that is used to verify the output of the oscilloscopes during the calibration process. The DMM manufacturer provides a detailed calibration certificate and specifies the DMM\'s accuracy and uncertainty. Considering the requirements of ISO/IEC 17025:2017, what is the MOST appropriate approach for Quantum Analytics to ensure the reliability of the DMM\'s measurements within the calibration process?

Accepted Answer

Perform a verification of the DMM's performance characteristics against the manufacturer's specifications, focusing on parameters relevant to its use in oscilloscope calibration, and document the results.

Question 7

MediCorp Solutions, a medical device manufacturer producing Class II devices, is experiencing significant variability in testing results from its in-house laboratory. This inconsistency is leading to concerns about the reliability of product quality control and potential non-conforming products reaching the market, raising significant red flags under ISO 13485:2016. Top management is seeking a solution to ensure the laboratory\'s competence and the reliability of its testing methods. Considering the need to improve the accuracy and consistency of test results, and to demonstrate compliance with relevant regulatory requirements, which of the following actions would be MOST effective in addressing the root causes of the problem and ensuring the long-term reliability of the laboratory\'s operations?

Accepted Answer

Implement ISO/IEC 17025:2017 to ensure the technical competence of the laboratory, focusing on method validation, measurement traceability, and a robust quality management system.

Question 8

A medical device manufacturer, \"MediCorp Innovations,\" is developing a new Class II medical device for the European market under the Medical Device Regulation (MDR). They plan to outsource biocompatibility testing to an external laboratory. MediCorp\'s Quality Manager, Anya Sharma, is evaluating potential testing labs. Considering the requirements of ISO 13485:2016 and the importance of ISO/IEC 17025:2017 in laboratory accreditation, what is Anya\'s *most* critical consideration regarding the testing laboratory\'s accreditation status to ensure compliance and minimize risk associated with the MDR requirements?

Accepted Answer

Anya must verify that the testing laboratory is accredited to ISO/IEC 17025:2017 with a scope that specifically covers the biocompatibility tests required for MediCorp's device and that MediCorp establishes acceptance criteria for the lab's performance.

Question 9

MedTech Solutions, a medical device manufacturer, outsources biocompatibility testing to an accredited third-party laboratory to ensure compliance with ISO 10993 and FDA 21 CFR Part 820 requirements for their newly developed implantable device. During a routine audit of MedTech Solutions\' quality system, it\'s discovered that the testing laboratory\'s validation records for the specific biocompatibility tests performed on the device are incomplete and do not fully demonstrate the suitability of the methods for the intended purpose and sample matrix. Considering the requirements of ISO/IEC 17025:2017 and the potential impact on MedTech Solutions, what is the MOST critical consequence of the testing laboratory\'s inadequate method validation?

Accepted Answer

Compromised data integrity, leading to potentially unreliable biocompatibility assessments and jeopardizing the manufacturer's ability to demonstrate regulatory compliance.

Question 10

BioAnalytica Labs, an ISO/IEC 17025:2017 accredited calibration laboratory, provides critical calibration services for medical device manufacturers. One of their key calibration processes relies on a specialized, aging piece of equipment that is essential for ensuring the accuracy of pressure sensors used in ventilators. The equipment is past its expected lifespan, and there is no readily available replacement or backup instrument. During a recent internal audit, Qian, the lead auditor, identified the reliance on this single piece of equipment as a significant risk to the laboratory\'s operations and accreditation. Management acknowledges the risk but has not yet implemented any specific mitigation measures, citing budget constraints and the perceived low likelihood of equipment failure. Considering the requirements of ISO/IEC 17025:2017 and its emphasis on risk management, what is the MOST appropriate immediate action that BioAnalytica Labs should take?

Accepted Answer

Develop and implement a comprehensive risk mitigation plan that includes preventive maintenance, performance monitoring, and a contingency plan for equipment failure, such as identifying an alternative calibration service.

Question 11

MedTech Innovations, a medical device manufacturer certified to ISO 13485:2016, utilizes QualAssure Labs, an ISO/IEC 17025:2017 accredited testing laboratory, for biocompatibility testing of their new implantable device. After several test batches, MedTech Innovations notices inconsistencies in the reported results for the same material batch across different test runs. Suspecting potential issues with QualAssure Labs\' testing methodologies, what is the MOST critical action MedTech Innovations should take, considering both their ISO 13485:2016 obligations and QualAssure Labs\' ISO/IEC 17025:2017 accreditation? Assume that the biocompatibility tests are within the scope of QualAssure Labs\' ISO/IEC 17025 accreditation. The inconsistent results are significantly impacting MedTech Innovation\'s risk assessment and product release timelines. Furthermore, regulatory submissions (e.g., FDA 510(k) equivalent) are dependent on these biocompatibility results.

Accepted Answer

Conduct a thorough audit of QualAssure Labs' method validation process specifically for the biocompatibility tests in question, focusing on validation data, statistical analysis, and adherence to relevant standards like ISO 10993.

Question 12

A bio-pharmaceutical company, \"MedTech Solutions,\" is seeking ISO/IEC 17025:2017 accreditation for its in-house testing laboratory, which performs critical quality control analyses on raw materials and finished products. During a preliminary gap analysis, the lead auditor identifies several areas where MedTech Solutions\' current risk management practices do not fully align with the standard\'s requirements. Specifically, while the laboratory has a general risk register, it lacks a documented procedure for systematically identifying and assessing risks related to measurement traceability and uncertainty of measurement. Furthermore, the existing risk mitigation strategies primarily focus on equipment failures and do not adequately address risks associated with personnel competence in performing complex analytical methods. Considering the requirements of ISO/IEC 17025:2017, what is the MOST critical action MedTech Solutions needs to take to address these gaps and ensure compliance with the standard\'s risk management requirements?

Accepted Answer

Develop and implement a documented procedure for risk assessment and mitigation that specifically addresses measurement traceability, uncertainty of measurement, and personnel competence, ensuring that all identified risks are systematically evaluated and controlled.

Question 13

\"Global Food Safety Testing,\" a food testing laboratory accredited to ISO/IEC 17025:2017, is conducting its annual internal audit program. The quality assurance manager, Mr. Javier Ramirez, is responsible for planning and executing the audits. Considering the requirements of ISO/IEC 17025:2017 and the importance of a risk-based approach, which of the following strategies would be MOST effective for Global Food Safety Testing to plan and conduct its internal audits?

Accepted Answer

Focus internal audits on high-risk areas identified through a systematic risk assessment, tailor audit criteria and checklists to address specific risks, evaluate audit findings in terms of their potential impact, implement corrective actions to address root causes, and verify the effectiveness of corrective actions.

Question 14

MediCorp, a medical device manufacturer pursuing ISO 13485:2016 certification, outsources biocompatibility testing of its raw materials to several external laboratories. As the lead implementer of ISO 13485:2016 within MediCorp, you are tasked with establishing a robust system for selecting and monitoring these laboratories to ensure the reliability of their testing data. Considering the principles and requirements of ISO/IEC 17025:2017, which of the following strategies would be the MOST effective in ensuring the competence and reliability of these external testing laboratories, directly impacting the quality and safety of MediCorp\'s medical devices while adhering to regulatory expectations such as those of the FDA and MDR? The selected strategy should be sustainable and auditable.

Accepted Answer

Prioritize laboratories holding ISO/IEC 17025 accreditation, supplemented by contractual agreements outlining specific requirements and periodic audits to verify ongoing compliance with both ISO/IEC 17025 and MediCorp's specific needs.

Question 15

Precision Medical Instruments (PMI), a manufacturer of surgical instruments, relies on an external calibration laboratory, Calibratech, to ensure the accuracy of its measurement equipment used in the manufacturing process. PMI is ISO 13485:2016 certified and requires Calibratech to comply with ISO/IEC 17025:2017. During a recent audit of Calibratech, PMI discovers that while Calibratech possesses calibration certificates for its reference standards, it lacks documented procedures for establishing and maintaining the traceability of these standards to national or international measurement standards. In this scenario, what is the MOST critical action PMI should take to ensure compliance with ISO 13485:2016 and maintain the integrity of its measurement traceability?

Accepted Answer

Accept the calibration certificates provided by Calibratech as sufficient evidence of traceability, assuming that Calibratech, as a specialized calibration laboratory, inherently maintains proper traceability practices, and continue using their services without further investigation.

Question 16

BioAnalytica, a medical device testing laboratory pursuing ISO/IEC 17025:2017 accreditation, is conducting a risk assessment of its testing processes. Dr. Anya Sharma, the quality manager, identifies a recurring issue: frequent malfunctions of a critical piece of testing equipment, the spectrophotometer, leading to delays and potential inaccuracies in test results. To align with the risk management principles outlined in ISO/IEC 17025:2017, which of the following actions should BioAnalytica prioritize as the MOST direct application of risk mitigation in this scenario? The laboratory has already documented the issue and its potential impact.

Accepted Answer

Implementing a comprehensive preventative maintenance program for the spectrophotometer, including regular calibration checks and proactive component replacements, to minimize the likelihood of future malfunctions and ensure accurate test results.

Question 17

MediCorp, a medical device manufacturer certified to ISO 13485:2016, outsources the validation of its sterilization processes to an external testing laboratory. Recognizing the critical impact of sterilization on product safety and efficacy, and acknowledging the requirements for control of outsourced processes outlined in ISO 13485:2016 section 4.1.5, MediCorp\'s quality manager, Anya Sharma, seeks to ensure the reliability and validity of the sterilization validation results. Which of the following actions would provide the MOST robust assurance that the outsourced sterilization validation meets the necessary quality and regulatory requirements?

Accepted Answer

Verifying that the external testing laboratory holds ISO/IEC 17025:2017 accreditation specifically for sterilization validation testing.

Question 18

BioTech Solutions, a medical device manufacturer, is developing a novel implantable device. They contract Quantum Analytics, an external testing laboratory accredited to ISO/IEC 17025:2017, to conduct biocompatibility testing required for regulatory submission. During the submission process, BioTech Solutions discovers discrepancies in the test results reported by Quantum Analytics. The regulatory agency raises concerns about the validity of the biocompatibility data. Considering BioTech Solutions is pursuing ISO 13485:2016 certification, how should BioTech Solutions address the situation, keeping in mind the relationship between ISO 13485:2016 and reliance on ISO/IEC 17025:2017 accredited labs, and the potential impact on their QMS and regulatory compliance?

Accepted Answer

BioTech Solutions should initiate a thorough investigation with Quantum Analytics to identify the root cause of the discrepancies, re-evaluate the affected biocompatibility data, and implement corrective actions within their QMS, ensuring documented evidence of the investigation and corrective actions is available for regulatory review and internal audits.

Question 19

A medical device testing laboratory accredited to ISO/IEC 17025:2017 is considering implementing a new, faster testing method for analyzing the chemical composition of materials. The new method promises to significantly reduce turnaround times and increase the laboratory\'s throughput. As the Lead Implementer, how should you approach the implementation of this new method to ensure compliance with ISO/IEC 17025:2017 regarding risk management?

Accepted Answer

Conduct a comprehensive risk assessment to identify potential risks associated with the new method, including potential errors, impact on data integrity, and the need for additional training, before implementing the method.

Question 20

Dr. Anya Sharma, the newly appointed Quality Manager at "MediTest Labs," a medical device testing facility seeking ISO/IEC 17025:2017 accreditation to enhance its credibility with regulatory bodies like the FDA and notified bodies in Europe, is tasked with establishing a comprehensive risk management framework. The lab performs a wide range of tests, including biocompatibility testing, electrical safety testing, and performance testing of medical devices. A recent internal assessment revealed potential vulnerabilities in the lab\'s measurement traceability and environmental control systems. Specifically, the calibration certificates for some key testing equipment lack clear traceability to national standards, and temperature fluctuations in the controlled environment chambers used for biocompatibility testing have exceeded acceptable limits on several occasions.

Given the requirements of ISO/IEC 17025:2017, which of the following represents the MOST appropriate and comprehensive approach for Dr. Sharma to address these identified risks and establish a robust risk management framework?

Accepted Answer

Implement a comprehensive risk assessment process that includes identifying potential failures in measurement traceability and environmental control, developing mitigation strategies such as using redundant calibration sources and implementing environmental monitoring systems, and establishing procedures for regular audits of the traceability system and environmental controls, all documented within the quality management system.

Question 21

BioCorp Diagnostics, a medical device manufacturer, relies on an external testing laboratory, AccuTest Labs, for biocompatibility testing of their new implantable device. AccuTest Labs is ISO/IEC 17025:2017 accredited. During a recent internal audit, BioCorp\'s quality manager, Anya Sharma, noted that AccuTest Labs had a detailed risk register identifying potential hazards, documented control measures, and a well-defined risk management process. However, Anya observed limited evidence demonstrating how AccuTest Labs\' risk management activities directly contributed to ensuring the reliability and accuracy of their biocompatibility test results. According to ISO/IEC 17025:2017, what is the *most* critical aspect of risk management that AccuTest Labs should prioritize to meet the standard\'s requirements and maintain BioCorp\'s confidence in their testing services, considering the regulatory scrutiny surrounding medical device biocompatibility?

Accepted Answer

Ensuring the validity of test results and the quality of laboratory services by proactively mitigating risks that could compromise accuracy and reliability.

Question 22

MedTech Solutions, a medical device manufacturer certified to ISO 13485:2016, outsources biocompatibility testing to Apex Laboratories, an ISO/IEC 17025:2017 accredited testing facility. During a recent audit of MedTech Solutions, the auditor identifies a discrepancy: Apex Laboratories\' internal risk assessment for a specific cytotoxicity test doesn\'t explicitly address potential patient harm resulting from false negative test results, a critical aspect highlighted in MedTech Solutions\' risk management documentation. Considering the integrated quality management system requirements of both standards and the potential impact on medical device safety, what is the MOST appropriate corrective action for MedTech Solutions\' Quality Manager, Javier, to initiate?

Accepted Answer

Javier should request Apex Laboratories to revise their risk assessment documentation to explicitly include the potential for patient harm due to false negative results and demonstrate how their testing protocols mitigate this specific risk, ensuring alignment with MedTech Solutions' risk management framework.

Question 23

Dr. Anya Sharma manages a testing laboratory specializing in biocompatibility assessments for medical devices. The lab is accredited to ISO/IEC 17025:2017. During a routine calibration check, a critical spectrophotometer used for quantifying leachable substances fails its calibration. The calibration technician notes that the instrument has been operating outside of acceptable tolerances for an undetermined period. The laboratory has used this spectrophotometer to generate results for several client projects over the past few months, all of which have been reported. Considering the requirements of ISO/IEC 17025:2017 and the lab\'s quality management system, what is the MOST appropriate immediate course of action for Dr. Sharma to take as the lead implementer?

Accepted Answer

Immediately investigate the potential impact of the out-of-calibration spectrophotometer on previously reported results, conduct a risk assessment to determine the validity of those results, and take corrective actions as needed, including client notification and retesting.

Question 24

Dr. Anya Sharma, the newly appointed Quality Manager at \'BioAssay Labs,\' is tasked with aligning the laboratory\'s operations with ISO/IEC 17025:2017. While reviewing the current risk management practices, she observes that the laboratory primarily reacts to identified non-conformities rather than proactively assessing potential risks. The existing system focuses heavily on corrective actions after an incident occurs, with limited documentation of preventative measures. Furthermore, risk assessments are conducted annually without considering changes in equipment, personnel, or testing methodologies. The laboratory\'s management believes that their current approach is sufficient, as they have successfully addressed all reported non-conformities in the past year. Dr. Sharma understands that this reactive approach does not fully align with the standard\'s requirements. Which of the following best describes the key deficiency in BioAssay Labs\' current risk management system according to ISO/IEC 17025:2017?

Accepted Answer

The laboratory's risk management system lacks a proactive approach to identifying and mitigating potential risks, focusing primarily on reactive corrective actions rather than preventative measures and continuous improvement.

Question 25

MediCorp, a medical device manufacturer, is developing a novel implantable cardiac device. They contract AccuTest Labs, an ISO/IEC 17025 accredited testing laboratory, to perform biocompatibility testing required for regulatory submission to the FDA. After receiving the test reports from AccuTest Labs, MediCorp\'s internal validation testing reveals inconsistencies with the data provided by AccuTest Labs. Specifically, MediCorp\'s internal tests show a higher rate of inflammatory response than reported by AccuTest Labs. Given that AccuTest Labs is ISO/IEC 17025 accredited, what is MediCorp\'s *most appropriate* next course of action regarding the biocompatibility data and its regulatory submission strategy, considering the potential impact on patient safety and regulatory compliance? The device is classified as Class III and requires rigorous pre-market approval.

Accepted Answer

MediCorp should independently verify the biocompatibility test results obtained from AccuTest Labs, despite their ISO/IEC 17025 accreditation, to ensure the reliability of the data for regulatory submissions and patient safety.

Question 26

NovaTech Medical, a manufacturer of surgical instruments, has recently restructured its organization. As part of this restructuring, the responsibility for reviewing and approving changes to critical suppliers has been delegated from the CEO to the Supply Chain Manager. As the ISO 13485 Lead Implementer, what action must top management (the CEO) take to ensure that the QMS remains effective with respect to supplier control, considering this delegation of responsibility?

Accepted Answer

Document the delegation of responsibility in the quality manual and assume that the Supply Chain Manager is competent to perform the task, without further oversight.

Question 27

Dr. Anya Sharma, the quality manager at \"Precision Medical Labs,\" is tasked with transitioning the lab\'s quality management system from ISO 9001:2015 to ISO/IEC 17025:2017 to achieve accreditation for their testing services. During a staff training session, a senior technician, Ben Carter, raises a concern about the differences in the requirements for risk management and measurement validation between the two standards. He argues that the lab already has a robust risk management system under ISO 9001:2015 and wonders if the transition will require significant additional effort. Furthermore, he questions whether the existing method validation procedures, which meet general industry practices, will suffice under the new standard. Considering the specific requirements of ISO/IEC 17025:2017, which of the following statements best describes the key differences that Dr. Sharma should highlight to Ben to clarify the transition requirements?

Accepted Answer

ISO/IEC 17025:2017 places a greater emphasis on measurement traceability and uncertainty of measurement, requiring rigorous calibration procedures and documented traceability chains, whereas ISO 9001:2015 primarily focuses on overall quality management systems without the same level of technical detail in measurement science.

Question 28

FutureForward Labs is proactively preparing for the future of laboratory testing. Which of the following strategies BEST reflects a forward-thinking approach to adapting to emerging trends and technologies in the laboratory industry, particularly when the laboratory supports medical device companies adhering to ISO 13485:2016?

Accepted Answer

Embrace digital transformation, explore the use of automation and artificial intelligence, and stay informed about future directions in laboratory accreditation and standards.

Question 29

Dr. Anya Sharma, the lead analyst at a medical device testing laboratory accredited to ISO/IEC 17025:2017, discovers that a junior technician, Kai Ito, has been routinely modifying a validated test method for biocompatibility testing without authorization or documentation. This modification involves altering the incubation period by 10% to expedite the testing process. The laboratory\'s quality manual explicitly requires adherence to validated methods and a formal change control process for any modifications. Dr. Sharma immediately halts the testing and initiates an investigation. Considering the requirements of ISO/IEC 17025:2017 and its implications for the laboratory\'s quality management system, what is the most appropriate immediate action regarding the test results obtained using the unapproved deviation?

Accepted Answer

All test results obtained using the unapproved deviation are questionable and must be investigated, risk assessed, and potentially re-validated before further use.

Question 30

BioAnalytica, a testing laboratory specializing in medical device biocompatibility assessments, is seeking ISO/IEC 17025:2017 accreditation to enhance its market credibility and ensure the reliability of its test results for medical device manufacturers adhering to ISO 13485:2016. During a recent risk assessment, the laboratory identified a high risk associated with the calibration of its critical analytical equipment, specifically a Gas Chromatography-Mass Spectrometer (GC-MS) used for detecting trace levels of potentially harmful substances leaching from medical devices. The risk assessment indicated that deviations in GC-MS calibration could lead to inaccurate quantification of leachates, potentially compromising the safety assessment of medical devices. However, during the subsequent management review, this specific risk was not adequately addressed, and no concrete actions were assigned to mitigate the calibration risk. Considering the requirements of ISO/IEC 17025:2017 and its role in supporting ISO 13485:2016 compliance, what is the MOST likely consequence of this oversight?

Accepted Answer

The laboratory's ability to demonstrate the validity of its test results related to biocompatibility and maintain ISO/IEC 17025:2017 accreditation is compromised due to inadequate risk management and potential for inaccurate results.

ISO 13485:2016 Lead Implementer Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 13485:2016 Lead Implementer Certification